Drug intelligence / Profile preview

CancerVax-Marker1-Marker2-Smart mRNA-lipid nanoparticle-Breast cancer

Development stage: Preclinical
Lead developer: CancerVax
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics

Overview

CancerVax's breast cancer immunotherapy is an experimental mRNA-based treatment currently in pre-clinical development. Part of the company's Universal Cancer Treatment Platform, the therapy utilizes "Smart mRNA" encapsulated in lipid nanoparticles (LNPs) to target two proprietary markers: Marker1, a cell surface protein, and Marker2, a cancer-specific genetic signature. The unique mechanism of action involves delivering mRNA that instructs breast cancer cells to express antigens typically associated with common viruses like measles or chickenpox. This "viral mimicry" or disguise is intended to trigger a robust immune response by activating the patient's existing immune memory against these viral pathogens, thereby directing the immune system to attack and eliminate the tumor cells. The program is slated to begin pre-IND animal studies in 2026.

Other names: CancerVax breast cancer immunotherapyBreast cancer program

Targets

MARK1 (Microtubule affinity regulating kinase 1)TACSTD2 (Tumor-associated calcium signal transducer 2)

Beyond the preview

Go deeper on CancerVax-Marker1-Marker2-Smart mRNA-lipid nanoparticle-Breast cancer.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CancerVax-Marker1-Marker2-Smart mRNA-lipid nanoparticle-Breast cancer.

Explore the full profile